Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

Leticia R. Cruz, Idania Baladron, Aliusha Rittoles, Pablo A. Diaz, Carmen Valenzuela, Raul Santana, Maria M. Vazquez, Ariadna Garcia, Deyli Chacon, Delvin Thompson, Gustavo Perera, Ariel Gonzalez, Rafael Reyes, Loida Torres, Jesus Perez, Yania Valido, Ralysmay Rodriguez, Dania M. Vazquez, View ORCID ProfileMauro Rosales, Ailyn C. Ramon, George V. Perez, Gerardo Guillen, View ORCID ProfileVerena Muzio, View ORCID ProfileYasser Perera, View ORCID ProfileSilvio E. Perea, ATENEA-Co-300 Group
doi: https://doi.org/10.1101/2020.09.03.20187112
Leticia R. Cruz
1 Luis Diaz Soto Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lrosarioc@infomed.sld.cu
Idania Baladron
2 Center for Genetic Engineering and Biotechnology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: idania.baladron@cigb.edu.cu
Aliusha Rittoles
1 Luis Diaz Soto Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: arittoles@gmail.com
Pablo A. Diaz
2 Center for Genetic Engineering and Biotechnology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pablo.dias@cigb.edu.cu
Carmen Valenzuela
3 Center for Molecular Immunology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: carmenv@cim.sld.cu
Raul Santana
1 Luis Diaz Soto Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rasantana@nauta.cu
Maria M. Vazquez
2 Center for Genetic Engineering and Biotechnology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: maria.vazquez@cigb.edu.cu
Ariadna Garcia
1 Luis Diaz Soto Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: arigarcia95@nauta.cu
Deyli Chacon
1 Luis Diaz Soto Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chaconmontano@infomed.sld.cu
Delvin Thompson
1 Luis Diaz Soto Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: delvinthompson@nauta.cu
Gustavo Perera
1 Luis Diaz Soto Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gperera@nauta.cu
Ariel Gonzalez
4 International Center of Health La Pradera;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: arielgolo@infomed.sld.cu
Rafael Reyes
5 National Institute of Oncology and Radiobiology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rafaele@infomed.sld.cu
Loida Torres
4 International Center of Health La Pradera;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: laborat@cislapradera.cu
Jesus Perez
1 Luis Diaz Soto Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: navalurgencias@infomed.sld.cu
Yania Valido
1 Luis Diaz Soto Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: navalurgencias@infomed.sld.cu
Ralysmay Rodriguez
1 Luis Diaz Soto Hospital;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: raly@infomed.sld.cu
Dania M. Vazquez
2 Center for Genetic Engineering and Biotechnology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dania.vazquez@cigb.edu.cu
Mauro Rosales
6 Faculty of Biology, University of Havana;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mauro Rosales
  • For correspondence: mauro.rosales@fbio.uh.cu
Ailyn C. Ramon
2 Center for Genetic Engineering and Biotechnology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ailyn.ramon@cigb.edu.cu
George V. Perez
2 Center for Genetic Engineering and Biotechnology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: george.perez@cigb.edu.cu
Gerardo Guillen
2 Center for Genetic Engineering and Biotechnology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gerardo.guillen@cigb.edu.cu
Verena Muzio
2 Center for Genetic Engineering and Biotechnology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Verena Muzio
  • For correspondence: verena.muzio@cigb.edu.cu
Yasser Perera
7 China-Cuba Biotechnology Joint Innovation Center;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yasser Perera
  • For correspondence: yasser.perera@outlook.com
Silvio E. Perea
2 Center for Genetic Engineering and Biotechnology;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Silvio E. Perea
  • For correspondence: silvio.perea@cigb.edu.cu
8 -
  • Abstract
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Purpose: The instrumental role of CK2 in the SARS-Cov2 infection has pointed out this protein kinase as a promising therapeutic target in Covid-19. Anti-SARS-Cov2 activity has been reported by CK2 inhibitors in vitro; however, any anti-CK2 clinical approach has been investigated in Covid-19. This exploratory trial aimed to explore safety and putative clinical benefit of CIGB-325, an anti-CK2 peptide previously assessed in cancer. Methods: A monocentric, parallel group design, therapeutic exploratory trial of intravenous CIGB-325 in adults hospitalized with Covid-19 was performed. Twenty patients were randomly assigned to receive CIGB-325 (2.5 mg/kg/day during 5-consecutive days) plus standard-of-care (10 patients) or standard-of-care (10 patients). Adverse events were classified by the WHO Adverse Reaction Terminology. Parametric and non-parametric statistical analyses were performed according to the type of variable. Considering the small sample size, differences between groups were estimated by Bayesian analysis. Findings: CIGB-325 induced transient mild and/or moderate adverse events like pruritus, flushing and rash in some patients. Both therapeutic regimens were similar respect to SARS-Cov2 clearance in nasopharynx swabs over the time. However, CIGB-325 significantly reduced the median number of pulmonary lesions (9.5 to 5.5, p = 0.042) at day 7 and proportion of patients with such effect was also higher according to Bayesian analysis (pDif > 0; 0.951). Additionally, CIGB-325 significantly reduced the CPK (p = 0.007) and LDH (p = 0.028) plasma levels at day 7. Implications: Our preliminary findings suggest that this anti-CK2 clinical approach could be combined with standard-of-care in Covid-19 thus warranting larger studies.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

IG/CIGB300I/CV/2001

Funding Statement

This work was supported in part by the British Embassy in Havana with funds of the International Programme of the Foreign, Commonwealth and Development Office (FCDO).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Ethics Committee for Clinical Research in the Luis Diaz Soto Hospital and Cuban Regulatory Agency (CECMED) approved the trial. The study complied with the Good Clinical Practices and the precepts established in the Declaration of the Helsinki World Medical Association. All patients met the inclusion criteria described in the protocol and signed the informed consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data referred in the manuscript is available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 22, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
Leticia R. Cruz, Idania Baladron, Aliusha Rittoles, Pablo A. Diaz, Carmen Valenzuela, Raul Santana, Maria M. Vazquez, Ariadna Garcia, Deyli Chacon, Delvin Thompson, Gustavo Perera, Ariel Gonzalez, Rafael Reyes, Loida Torres, Jesus Perez, Yania Valido, Ralysmay Rodriguez, Dania M. Vazquez, Mauro Rosales, Ailyn C. Ramon, George V. Perez, Gerardo Guillen, Verena Muzio, Yasser Perera, Silvio E. Perea, ATENEA-Co-300 Group
medRxiv 2020.09.03.20187112; doi: https://doi.org/10.1101/2020.09.03.20187112
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
Leticia R. Cruz, Idania Baladron, Aliusha Rittoles, Pablo A. Diaz, Carmen Valenzuela, Raul Santana, Maria M. Vazquez, Ariadna Garcia, Deyli Chacon, Delvin Thompson, Gustavo Perera, Ariel Gonzalez, Rafael Reyes, Loida Torres, Jesus Perez, Yania Valido, Ralysmay Rodriguez, Dania M. Vazquez, Mauro Rosales, Ailyn C. Ramon, George V. Perez, Gerardo Guillen, Verena Muzio, Yasser Perera, Silvio E. Perea, ATENEA-Co-300 Group
medRxiv 2020.09.03.20187112; doi: https://doi.org/10.1101/2020.09.03.20187112

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (415)
  • Dentistry and Oral Medicine (70)
  • Dermatology (48)
  • Emergency Medicine (144)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4861)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (676)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (630)
  • Health Policy (321)
  • Health Systems and Quality Improvement (206)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5343)
  • Intensive Care and Critical Care Medicine (331)
  • Medical Education (93)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (686)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (208)
  • Oncology (440)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (781)
  • Public and Global Health (1817)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)